SER

Serina Therapeutics Inc

Oct 13 • 04:00PM ET

5.01

-0.30 -5.65 %

Healthcare • Biotechnology • USA • AMEX

Peers: MRK LLY BMY JNJ AMGN PFE GILD REGN VRTX BIIB

Index	-	P/E	-	EPS (ttm)	-5.94	Insider Own	72.23%	Shs Outstand	10.14M	Perf Week	-3.47%
Market Cap	51.36M	Forward P/E	-	EPS next Y	-1.77	Insider Trans	-1.33%	Shs Float	2.85M	Perf Month	-3.47%
Enterprise Value	50.46M	PEG	-	EPS next Q	-0.53	Inst Own	4.06%	Short Float	2.05%	Perf Quarter	-5.47%
Income	-6.28M	P/S	395.08	EPS this Y	-41.06%	Inst Trans	4.35%	Short Ratio	0.45	Perf Half Y	4.38%
Sales	0.13M	P/B	-	EPS next Y	16.90%	ROA	-63.92%	Short Interest	0.06M	Perf YTD	0.00%
Book/sh	-0.31	P/C	8.50	EPS next 5Y	4.14%	ROE	-	52W High	8.14 -38.45%	Perf Year	-27.71%
Cash/sh	0.59	P/FCF	-	EPS past 3/5Y	42.71% 33.30%	ROIC	-316.00%	52W Low	3.81 31.50%	Perf 3Y	-77.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	11.87% -49.63%	Gross Margin	-36.51%	Volatility	5.26% 5.21%	Perf 5Y	-83.84%
Dividend TTM	-	EV/Sales	388.15	EPS Y/Y TTM	55.34%	Oper. Margin	-11951.59%	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.24	Sales Y/Y TTM	34.04%	Profit Margin	-4983.33%	RSI (14)	45.09	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.24	EPS Q/Q	80.95%	SMA20	-2.13%	Beta	1.09	Target Price	13.00
Payout	-	Debt/Eq	0.20	Sales Q/Q	2500.00%	SMA50	-3.93%	Rel Volume	0.28	Prev Close	5.31
Employees	13	LT Debt/Eq	0.10	Earnings	Aug 11 AMC	SMA200	-4.65%	Avg Volume	128.76K	Price	5.01
IPO	Nov 29, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	-55.29% -	Trades		Volume	35,852	Change	-5.65%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-14-25	Initiated	H.C. Wainwright	Buy	$15

Oct-08-25 11:00AM	Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors (GlobeNewswire)
Oct-06-25 04:15PM	Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease (GlobeNewswire)
Sep-09-25 03:20PM	Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease (GlobeNewswire)
Sep-08-25 06:00AM	Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-26-25 04:52AM	These Stocks Are Moving the Most Today: Interactive Brokers, Talen Energy, Palantir, Nvidia, Serina Therapeutics, and More (Barrons.com)
04:15PM	Loading…
Aug-25-25 04:15PM	Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway (GlobeNewswire)
Aug-11-25 04:30PM	Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -7.44% +7.06%
Jul-29-25 06:44AM	Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD) (GlobeNewswire)
Jul-28-25 06:00AM	Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire) +5.83%
Jul-10-25 04:10PM	Serina Therapeutics Makes Grant to New Employee Under Inducement Plan (GlobeNewswire)
Jul-01-25 04:15PM	Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting (GlobeNewswire)
Jun-23-25 07:24PM	Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025 (GlobeNewswire) +5.95%
Jun-17-25 08:30PM	UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42 (GlobeNewswire)
06:00AM	Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 (GlobeNewswire)
Jun-09-25 04:05PM	Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" (GlobeNewswire)
04:50PM	Loading…
May-22-25 04:50PM	Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors (GlobeNewswire) +8.87%
May-14-25 03:15PM	Serina Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
May-08-25 04:23PM	Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-29-25 06:00AM	Serina Therapeutics to Present at JonesResearch Virtual CNS Day (GlobeNewswire)
Apr-15-25 06:30AM	Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit (GlobeNewswire)
Apr-08-25 04:30PM	Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease (GlobeNewswire)
Apr-07-25 06:30AM	Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
Mar-24-25 04:30PM	Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
06:30AM	Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting (GlobeNewswire)
Feb-12-25 04:15PM	Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors (GlobeNewswire)
Feb-03-25 04:30PM	Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients (GlobeNewswire) -5.91%
Jan-15-25 04:05PM	Serina Therapeutics Announces Sale of UniverXome Subsidiary (GlobeNewswire)
Jan-14-25 05:25PM	Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors (GlobeNewswire)
Dec-16-24 06:00AM	Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024 (GlobeNewswire) -7.98%
Dec-11-24 06:05AM	Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity and Toxicity Summit (GlobeNewswire) -9.16%
06:05AM	Loading…
06:05AM	Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit (GlobeNewswire)
Dec-02-24 05:22PM	Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients (GlobeNewswire) -9.52% +19.16%
Nov-12-24 05:00PM	Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-11-24 05:40PM	Serina Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +20.87%
Oct-02-24 08:30AM	Serina Therapeutics to Present at the 14th Annual Injectables Summit (GlobeNewswire)
Sep-04-24 06:42PM	Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-20-24 07:01PM	Director Gregory Bailey Acquires 19,200 Shares of Serina Therapeutics Inc (SER) (GuruFocus.com)
Aug-09-24 04:15PM	Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -5.17% -10.13%
Jul-29-24 08:30AM	Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit (GlobeNewswire)
Jul-18-24 05:00PM	Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation (GlobeNewswire) -18.15% +9.84%
May-15-24 07:30AM	Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinsons Disease (GlobeNewswire)
May-14-24 04:05PM	Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +11.13%
Apr-17-24 04:05PM	Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman (GlobeNewswire) -9.64%
Mar-26-24 05:04PM	Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics (GlobeNewswire) -11.90% +33.98%

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moreadith Randall	Chief Scientific Officer	Aug 26 '25	Option Exercise	0.06	45,632	2,738	45,632	Aug 27 05:16 PM
Moreadith Randall	Chief Scientific Officer	Aug 25 '25	Option Exercise	0.06	2,042	123	2,042	Aug 27 05:16 PM
Moreadith Randall	Chief Scientific Officer	Aug 26 '25	Sale	7.01	45,632	319,880	0	Aug 27 05:16 PM
Moreadith Randall	Chief Scientific Officer	Aug 25 '25	Sale	5.65	2,042	11,537	0	Aug 27 05:16 PM
Moreadith Randall	Chief Scientific Officer	Aug 18 '25	Option Exercise	0.06	2,227	134	2,227	Aug 20 05:13 PM
Moreadith Randall	Chief Scientific Officer	Aug 20 '25	Option Exercise	0.06	2,077	125	2,077	Aug 20 05:13 PM
Moreadith Randall	Chief Scientific Officer	Aug 18 '25	Sale	5.25	2,227	11,692	0	Aug 20 05:13 PM
Moreadith Randall	Chief Scientific Officer	Aug 20 '25	Sale	5.10	2,077	10,593	0	Aug 20 05:13 PM
Moreadith Randall	Chief Scientific Officer	Aug 12 '25	Option Exercise	0.06	5,500	330	5,500	Aug 14 04:27 PM
Moreadith Randall	Chief Scientific Officer	Aug 12 '25	Sale	5.25	5,500	28,875	0	Aug 14 04:27 PM
Moreadith Randall	Chief Scientific Officer	Aug 04 '25	Option Exercise	0.06	5,500	330	5,500	Aug 06 05:22 PM
Moreadith Randall	Chief Scientific Officer	Aug 04 '25	Sale	5.17	5,500	28,435	0	Aug 06 05:22 PM
Moreadith Randall	Chief Scientific Officer	Jul 29 '25	Option Exercise	0.06	4,196	252	4,196	Jul 30 01:47 PM
Moreadith Randall	Chief Scientific Officer	Jul 29 '25	Sale	6.50	4,196	27,274	0	Jul 30 01:47 PM
Moreadith Randall	Chief Scientific Officer	Jul 28 '25	Option Exercise	0.06	6,500	390	6,500	Jul 29 06:10 AM
Moreadith Randall	Chief Scientific Officer	Jul 28 '25	Sale	5.89	6,500	38,285	0	Jul 29 06:10 AM
Moreadith Randall	Chief Scientific Officer	Jul 21 '25	Option Exercise	0.06	6,500	390	6,500	Jul 22 10:25 AM
Moreadith Randall	Chief Scientific Officer	Jul 21 '25	Sale	5.34	6,500	34,710	0	Jul 22 10:25 AM
Moreadith Randall	Chief Scientific Officer	Jul 14 '25	Option Exercise	0.06	6,500	390	6,500	Jul 17 10:40 AM
Moreadith Randall	Chief Scientific Officer	Jul 14 '25	Sale	5.01	6,500	32,565	0	Jul 17 10:40 AM
Moreadith Randall	Chief Scientific Officer	Jul 07 '25	Option Exercise	0.06	6,500	390	6,500	Jul 09 10:47 AM
Moreadith Randall	Chief Scientific Officer	Jul 07 '25	Sale	5.67	6,500	36,855	0	Jul 09 10:47 AM
Moreadith Randall	Chief Scientific Officer	Jun 30 '25	Option Exercise	0.06	6,500	390	6,500	Jul 02 11:00 AM
Moreadith Randall	Chief Scientific Officer	Jun 30 '25	Sale	5.78	6,500	37,570	0	Jul 02 11:00 AM
Moreadith Randall	Officer	Jun 30 '25	Proposed Sale	5.78	99,674	576,056		Jun 30 04:28 PM
Bailey Gregory	Director	Dec 17 '24	Buy	4.59	3,866	17,745	67,243	Dec 19 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SER

Serina Therapeutics Inc

Upgrade your FINVIZ experience